Tag: Marketwatch

Feb 13
Newell Brands' stock jumps after profit and revenue beat expectations, while gross margin fell

Shares of Newell Brands Inc. NWL, +11.07% surged 3.3% in premarket trading Friday, after the consumer good company, with brands including Rubbermaid, Sharpie, Elmer’s and Mr. Coffee, reported fourth-quarter profit and revenue that beat expectations, while providing a mixed outlook for the current quarter and the full year. Net income fell $96 million, or 22 […]

Feb 13
Under Armour earnings beat expectations, shifts fiscal year

Under Armour Inc. UA, -11.37% UAA, -12.49% reported fourth-quarter net income of $109.7 million, or 23 cents per share, down from $184.5 million, or 40 cents per share, last year. Adjusted EPS of 14 cents beat the FactSet consensus for 6 cents. Revenue of $1.529 billion was up from $1.404 billion and ahead of the […]

Feb 13
Cantor Fitzgerald cuts price target on Aurora Cannabis

Cantor Fitzgerald analyst Pablo Zuanic on Friday reiterated a neutral rating on Aurora Cannabis ACB, -2.18% ACB, -1.88% and cut his 12-month price target to C$7.60 from C$10.75 due to reduced sales estimates. The company said it expects to reach positive Ebitda by the first half of fiscal year 2023, but Zuanic said the company […]

Feb 13
Zillow to cut workforce 25% in 2022, after growing by more than 45% last year

Zillow Group Inc. Z, +13.55% ZG, +12.66% said it expects to cut its workforce by 25% this year, as a result of the previously announced wind down of Zillow Offers operations, but that followed a more than 45% jump in its workforce in 2021. In the real estate information company’s 10-K annual report filed late […]

Feb 13
Alliance Global Partners initiates coverage of Verano with buy rating

Alliance Global Partners on Friday launched coverage of U.S.-based cannabis multi-state operator Verano Holdings Corp. VRNOF, +1.05% VRNO, +1.20% with a buy rating and a price target of C$30 ($23.61) a share. Analyst Aaron Grey said the company is trading at a discount relative to its peers. “We believe the company will continue to close […]

Feb 12
Goodyear Tire stock jumps after profit rises well above expectations

Shares of Goodyear Tire & Rubber Co. GT, -27.44% jumped 4.0% in premarket trading Friday, after the tire maker reported fourth-quarter profit that rose well above expectations as revenue growth to a near 10-year high and higher selling prices helped offset inflationary cost pressures. Net income increased to $553 million, or $1.93 a share, from […]

Feb 12
Goldman Sachs Asset Management selling Financeit to Wafra for undisclosed sum

Financeit Canada Inc. said Friday it agreed to be acquired by private equity firm Wafra Capital Partners Inc. for an undisclosed sum from seller Goldman Sachs Asset Management, a unit of Goldman Sachs Group Inc. GS, -2.03%. The deal comes after Financeit added more than 1,100 new merchant partners, processed 115,000 loan applications, and funded […]

Feb 12
Gilead says in-vitro study shows its COVID-19 drug Veklury is active against omicron

Shares of Gilead Sciences Inc. GILD, +0.45% gained 0.6% in premarket trading on Friday after the company said Veklury, its COVID-19 drug, demonstrated in-vitro activity against omicron and 9 other variants. The research, which was announced in a news release on Friday morning, was published Thursday as a preprint. Gilead said the study has also […]

Feb 12
Twitter announces agreements with Morgan Stanley, Wells Fargo for $2 billion in accelerated share repurchases

Twitter Inc. TWTR, -3.34% said Friday morning that it has entered into agreements with Morgan Stanley & Co. MS, -2.79% and Wells Fargo Bank WFC, -1.25% to conduct $2 billion in accelerated share repurchases. The company previously announced a day earlier that it would launch a $2 billion accelerated repurchase program as part of a […]

Feb 12
SVB Leerink analyst doesn't expect cancer drug developed by Innovent and Lilly to be approved

Investors should expect to see fewer Food and Drug Administration approvals of copycat PD-L1 therapies after an advisory committee recommended against approving an experimental cancer drug, according to SVB Leerink analysts. The drug in question, sintilimab, is being developed by Innovent Biologics Inc. 1801, -7.47%, a Chinese drug maker, and Eli Lilly & Co. LLY, […]